Guangzhou Baiyunshan Pharmaceutical Holdings (00874) subsidiary has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.

19:14 09/01/2025

Baiyunshan (00874) announced that recently, its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyun...

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. BYS30 granules is a class 1 innovative traditional Chinese medicine compound formulation developed by Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory, indicated for knee osteoarthritis.

Ningbo Shanshan (600884.SH) may see a change in its controlling shareholder to Wanwei Group.

Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.

Ningbo Shanshan (600884.SH) may see a change in its controlling shareholder to Wanwei Group.

Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.